Abstract
BackgroundEvidence about the effectiveness of the tumor necrosis factor inhibitor adalimumab (ADA) in pediatric patients with non-infectious intermediate uveitis/pars planitis, posterior uveitis and panuveitis is still limited.ObjectivesAim of this study...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have